课题基金 / 基金详情

IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER

IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER
IGF::OT::IGF 他汀类药物治疗可减少从肝硬化到癌症的疾病进展
批准号：
9915354
负责人：
SEEMA KHAN
金额：
$5.74万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
项目状态：
已结题
起止时间：
2016-09-15 至 2019-09-14
来源：
https://reporter.nih.gov/project-details/9915354
关键词：
AFP geneBile AcidsClinicDisease ProgressionEvaluationHepatologyInterleukin-6InterventionLiverLiver CirrhosisLiver diseasesMalignant NeoplasmsMedical centerModelingParticipantPatientsPhasePlacebosPrimary carcinoma of the liver cellsSerumSimvastatinUniversitiesWaiting Listsdouble-blind placebo controlled trialliver transplantationrecruit

项目摘要

项目成果

SEEMA KHAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The proposed study is a Phase IIb, double-blinded, placebo-controlled trial of a statin to evaluate the impact of statin treatment on disease progression in 80 patients with liver cirrhosis who have a current Model for End-Stage Liver Disease (MELD) ≤ 20 and no evidence of Hepatocellular carcinoma (HCC). Participants shall be recruited from hepatology clinics at Cedar Sinai Medical Center (CSMC) and Northwestern University (NWU) and shall include patients who are currently waitlisted, or under evaluation, for a liver transplant.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CONTRACT TITLE - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
CONTRACT TITLE - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
海外基金